The current recommendation of Buy for Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is the result of using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. VRTX has maintained this ranking for 2 months.
VRTX is one of 344 companies within the Biotechnology GICS industry group, which is in turn part of the 783 company GICS Health Care sector. VRTX has a market value of $40.7 billion which is in the top decile in its industry group Currently, the stock's Portfolio Grader ranking places it 50 among the 344 companies in this industry group, putting in the top quartile.
The Health Care sector is ranked number 8 among the 12 sectors in the Portfolio Grader universe putting it in the third quartile of all the GICS sectors. The Biotechnology industry group is ranked 54 among the 69 industry groups within the GICS sectors, placing it well below-average in terms of the Navellier scoring system.
VRTX has achieved above-average scores in 4 of the 8 fundamental areas evaluated by Portfolio Grader and average or below-average grades in 4 of the areas used in the ranking of company stocks.
VRTX's operational scores provide mixed results with a ranking for sales growth that is well above the industry average but rankings for operating margin and earnings growth are below average. Scores for visibility of earnings are mixed, with rankings for earnings surprises and earnings momentum that are better than average, while the score for earnings revisions is worse than average. VRTX's grade for return on equity is better than its industry group average but its ranking for cash flow is below-average. These fundamental scores give Vertex Pharmaceuticals a position in the top decile of the industry group.
Portfolio Grader uses the Navellier Proprietary Quantitative Score to view VRTX's shares from the viewpoint of risk/reward. This unique scoring approach balances the relative value of VRTX's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Using this risk/reward calculation, the company currently scores above-average in its industry group compared to its peers.
Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'. Explore the tool here.
Commentary provided by UpTick Data Technologies.
